NCT02254239 is a Phase 1 clinical trial of Brentuximab Vedotin in Recurrent Hodgkin Lymphoma, sponsored by Mayo Clinic.

Who is sponsoring NCT02254239?

NCT02254239 is sponsored by Mayo Clinic.

What drugs are being tested in NCT02254239?

Interventions in NCT02254239: Brentuximab Vedotin, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study.

What condition does NCT02254239 study?

NCT02254239 studies Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma.

Is NCT02254239 still recruiting?

NCT02254239 is currently terminated. Last updated 12 December 2019.

Last reviewed 2019-12-12 · How we verify

NCT02254239

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Terminated Phase 1 Last updated 12 December 2019

What this trial tests

Phase 1 trial testing Brentuximab Vedotin in Recurrent Hodgkin Lymphoma in 10 participants. Terminated before completion.

Timeline

4 February 2016

Primary endpoint
12 December 2018

12 December 2018

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	4 February 2016
Primary completion	12 December 2018
Estimated completion	12 December 2018
Sites	1 location across United States

Drugs / interventions tested

Brentuximab Vedotin — full drug profile →
Everolimus (everolimus) — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Pharmacological Study — full drug profile →

Conditions studied

Recurrent Hodgkin Lymphoma — all drugs for Recurrent Hodgkin Lymphoma →
Refractory Hodgkin Lymphoma — all drugs for Refractory Hodgkin Lymphoma →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Recurrent Hodgkin Lymphoma or Refractory Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial studies the side effects and the best dose of everolimus when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has come back (relapsed) or is not responding to treatment (refractory). Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Brentuximab vedotin may interfere with the ability of cancer cells to grow and spread by binding to a protein on the surface of cancer cells and then releasing a cancer-killing substance to them. Giving everolimus together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.
Berger GK, McBride A, Lawson S, Royball K, et al · · 2017 · cited 58× · PMID 28010897 · DOI 10.1016/j.critrevonc.2016.11.009
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma.
Johnston PB, Pinter-Brown LC, Warsi G, White K, et al · · 2018 · cited 39× · PMID 29774169 · DOI 10.1186/s40164-018-0103-z
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A, Younes A. · · 2016 · cited 23× · PMID 26841013 · DOI 10.1097/ppo.0000000000000168
Current advances in Hodgkin's lymphoma.
Vadakara J, Andrick B. · · 2019 · cited 4× · PMID 30993260 · DOI 10.1016/j.cdtm.2019.02.003

Verify or expand the search:

Other trials of Brentuximab Vedotin

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting
NCT06831370 — A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India · Phase 4 · recruiting
NCT05711628 — A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Re · Phase 3 · withdrawn

Other recruiting trials for Recurrent Hodgkin Lymphoma

Currently open trials in the same condition.

NCT05272384 — Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma · Phase 1 · recruiting
NCT04871607 — Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Prima · Phase 2 · recruiting
NCT04640779 — Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or R · Phase 1 · active not recruiting
NCT03418038 — Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Le · Phase 2 · recruiting
NCT03016871 — Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapse · Phase 2 · active not recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02254239 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 12 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02254239.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing